Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.035 CAD | 0.00% | 0.00% | +16.67% |
Valuation
Fiscal Period: September | 2023 |
---|---|
Capitalization 1 | 3.202 |
Enterprise Value (EV) 1 | 2.595 |
P/E ratio | -2.45 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | - |
EV / FCF | -3,823,205 x |
FCF Yield | -0% |
Price to Book | 13.6 x |
Nbr of stocks (in thousands) | 80,053 |
Reference price 2 | 0.0400 |
Announcement Date | 30/01/24 |
Income Statement Evolution (Annual data)
Fiscal Period: September | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales | - | - | - |
EBITDA | - | - | - |
EBIT 1 | -0.6837 | -1.13 | -1.178 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -1.948 | -1.132 | -1.278 |
Net income 1 | -1.948 | -1.132 | -1.278 |
Net margin | - | - | - |
EPS 2 | -0.0349 | -0.0149 | -0.0163 |
Free Cash Flow | - | -0.3612 | -0.6788 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 18/01/22 | 30/01/23 | 30/01/24 |
Balance Sheet Analysis
Fiscal Period: September | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | - | - | - |
Net Cash position 1 | 2.36 | 1.57 | 0.61 |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow | - | -0.36 | -0.68 |
ROE (net income / shareholders' equity) | - | -65% | -172% |
ROA (Net income/ Total Assets) | - | -35.3% | -64.6% |
Assets 1 | - | 3.212 | 1.977 |
Book Value Per Share 2 | 0.0300 | 0.0200 | 0 |
Cash Flow per Share 2 | 0.0300 | 0.0200 | 0.0100 |
Capex | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 18/01/22 | 30/01/23 | 30/01/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+16.67% | 2.05M | |
+9.65% | 3,064B | |
+6.79% | 83.88B | |
+4.74% | 77.63B | |
-13.91% | 53.97B | |
+23.12% | 47.08B | |
-24.39% | 46.81B | |
+23.22% | 43.34B | |
+62.94% | 37.9B | |
-33.46% | 19.46B |
- Stock Market
- Equities
- DMED Stock
- Financials Diagnamed Holdings Corp.